Dongcheng Pharmaceutical's 2026 interim net profit reaches 93.7401 million yuan

Earnings
โดย Jiemian·CN·Read original
Summary · why it matters

Dongcheng Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 93.7401 million yuan. The company's total operating revenue was 1.309 billion yuan, down 5.41% year-on-year; net cash inflow from operating activities was 62.2854 million yuan, down 76.72% year-on-year. The company's latest asset-liability ratio was 42.07%, gross margin was 53.06%, and diluted earnings per share was 0.11 yuan.

Impact on stocks 1

Others▼ · 1 stocks
© 2026 MarketDXNews